Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLMRGH)

Drug Name

Saliphenylhalamide Drug Info

Synonyms

RTA-203; Saliphenylhalamide (cancer); Saliphenylhalamide (cancer), Reata; V-ATPase inhibitor (cancer), Reata; Vacuolar H+-ATPase inhibitors (anticancer), Reata

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

Cross-matching ID

PubChem CID: 11271117
TTD Drug ID: DMLMRGH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gastric H(+)/K(+) ATPase alpha (ATP4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexlansoprazole	DM1DBV5	Erosive esophagitis	DA25.0	Approved	[3]
Rabeprazole	DMMZXIW	Bacterial infection	1A00-1C4Z	Approved	[4]
AG-SPT201	DMJRQDG	Ulcerative colitis	DD71	Phase 3	[5]
API-023	DM6P93J	Gastroesophageal reflux disease	DA22.Z	Phase 1	[2]
PA-10040	DMELTM2	Cardiovascular disease	BA00-BE2Z	Investigative	[2]
CA-50040	DMCLN6M	Colorectal cancer	2B91.Z	Investigative	[2]
ARH-1029	DM8NETP	Helicobacter infection	DA42-DA63	Investigative	[2]
OPC-22575	DMO4WH9	Ulcerative colitis	DD71	Investigative	[2]
CDRI-85/92	DMQDA5W	Stomach ulcer	DA60.Z	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase alpha (ATP4A)	TTF1QVM	ATP4A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
3	Clinical pipeline report, company report or official report of Takeda (2009).
4	Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
5	Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.